Enrolling Now - 7
Protocol EP0093
An Open-Label, Multicenter, Extension Study To Evaluate the Efficacy And Safety of Padsevonil As Adjuntive Treatment of Focal-Onset Seizures In Adult Subjects with Drug-Resistant Epilepsy.
Sponsor: UCB Pharma
PI: Marcelo Lancman, MD
INCLUSION: (all should be YES)
* Is ≥ 18 years of age?
* Has completed 1 of the previous PSL studies which allow access to the present Study
* Female subjects willing to follow an efficient form of contraception for the duration of the study and for a period of 3 months after their final dose of PSL.
EXCLUSION (all should be NO)
* Any lab abnormalities or subject has any severe medical, neurological, or psychiatric conditions, which may have an impact on the safety of the subjects.
* Active suicidal thoughts
* Abnormal ECg findings
* History of unexplained syncope or a family history of sudden death due to long QT interval